Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: Recommendations of the international AIDS society-USA panel

American Journal of Ophthalmology

Volumn 127, Issue 3, 1999, Pages 329-339

  Martin, Daniel F ^a,m   Dunn, James P ^b,m   Davis, Janet L ^c   Duker, Jay S ^d   Engstrom Jr , Robert E ^e   Friedberg, Dorothy N ^f   Jaffe, Glenn J ^g   Kuppermann, Baruch D ^h   Polis, Michael A ⁱ   Whitley, Richard J ^j   Wolitz, Richard A ^k   Benson, Constance A ^l  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j University of Alabama at Birmingham   (United States)

^k KAISER PERMANENTE   (United States)

^l UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^m International AIDS Society USA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL SURVIVAL; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE SEVERITY; DRUG IMPLANT; DRUG POTENCY; ENDOPHTHALMITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PATIENT COUNSELING; PRIORITY JOURNAL; RETINA DETACHMENT; RETINITIS; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VITREOUS HEMORRHAGE;

EID: 0033105523     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(98)00441-3     Document Type: Note

References (79)

1. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114:821-827.
2. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993;115:575-582.
3. Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-1227.
4. Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy. Arch Intern Med 1998;158:957-969.
5. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial 4: Visual outcomes. Ophthalmology 1994;101:1250-1261.
6. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995;333:615-620.
7. Lalezari J, Friedberg D, Bisset J, et al. A comparison of the safety and efficacy of 3G, 4.5G, and 6G doses of oral ganciclovir versus IV ganciclovir for maintenance treatment of cytomegalovirus retinitis. In: XIth International Conference on AIDS, Vancouver, July 7-12; 1996. Abstract Th.B.305.
8. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997;126:257-263.
9. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med 1997;126:264-274.
10. Smith TJ, Pearson PA, Blandford DL, et al. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 1992;110:255-258.
11. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 1994;112:1531-1539.
12. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: Implications for therapy. J Infect Dis 1993;168:1506-1509.
13. Arevalo JF, Gonzales C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscamet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995;172:951-956.
14. Davis J, Gautier S, O'Grady O, Parel JM. Intravitreal ganciclovir concentration after oral intravenous and intravitreal administration in AIDS patients with cytomegalovirus retinitis: Implications for therapy. Invest Ophthalmol Vis Sci 1997;38(4, suppl):1100.
15. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997;337:83-90.
16. Roth DB, Feuer WJ, Blenke AJ, Davis JL. Treatment of recurrent cytomegalovirus retinitis with the ganciclovir implant. Am J Ophthalmol 1999;127:276-282.
17. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the international AIDS society-USA panel. JAMA 1998;280:78-86.
18. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents: November 5, 1997. MMWR Morb Mortal Wkly Rep 1998;47:RR-5.
19. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-549.
20. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-1017.
21. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200/fμL or less. N Engl J Med 1997;337:725-733.
22. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
23. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
24. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
25. Jabs DA, Bartlett JG. AIDS and ophthalmology: A period of transition. Am J Ophthalmol 1997;124:227-233.
26. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis [letter]. JAMA 1997;277:1519.
27. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated with protease inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997;124:199-205.
28. Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998;105:1259-1264.
29. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126:817-822.
30. Davis JL, Tabandeh H, Feuer WJ. Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant. Am J Ophthalmol 1999;127:283-287.
31. Gross PA, Barren TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994;18:421.
32. Engstrom RE, Holland GN. Local therapy for cytomegalovirus retinopathy. Am J Ophthalmol 1995;120:376-385.
33. Cochereau-Massin I, LeHoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991;98:1348-1353.
34. Young S, Morlet N, Besesn G, et al. High-dose (2000 (μg) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology 1998;105:1404-1410.
35. Diaz-Llopis M, Espana E, Munoz G, et al. High dose intravitreal foscamet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994;78:120-124.
36. Muccioli C, Goldstein DA, Johnson DW, et al. Fomivirsen safety and efficacy in the treatment of cytomegalovirus retinitis: A phase 3, controlled, multicenter study comparing immediate versus delayed treatment. In: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 1-5, 1998. Abstract LB6.
37. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ, the UCLA Cytomegalovirus Retinopathy Study Group. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retininopathy: Use of a standardized system for the assessment of disease outcome. Arch Ophthalmol 1989;107:1759-1766.
38. Stanley HD, Charlebois E, Harb G, Jacobson MA. Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease. J Acquir Immune Defic Syndr 1994;7:272-278.
39. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-220.
40. Martin D, Kuppermann B, Wolitz R, Palestine C, Robinson C. Combined oral ganciclovir (GCV) and intravitreal GCV implant for treatment of patients with cytomegalovirus (CMV) retinitis: A randomized, controlled study. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, December 28-October 1, 1997. Abstract LB-9.
41. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998;177:1080-1083.
42. Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4+ T-cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-1187.
43. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-719.
44. Dunn JP, MacCumber MW, Forman MS, et al. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol 1995;119:587-596.
45. Liu W, Kuppermann BD, Martin DF, Wolitz RA, Margolis TP. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir resistant retinitis. J Infect Dis 1998;177:1176-1181.
46. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996;114:23-33.
47. Marx JL, Kapusta MA, Patel SS, et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol 1996;114:815-820.
48. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: Use of an intravitreal device. Arch Ophthalmol 1992;110:188-195.
49. Anand R, Nightingale SD, Fish RH, Smith TJ, Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol 1993;111:223-227.
50. Hatton MP, Duker JS, Reichel E, et al. Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant. Retina 1998;18:50-55.
51. Kuppermann BD, Martin DF, Gordon JF, Stoecker JF, for the Ganciclovir Implant Study Group. Efficacy of the ganciclovir implant for the treatment of relapsing cytomegalovirus retinitis. In: 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997. Abstract.
52. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-563.
53. Morlet N, Young S, Naidoo D, Graham G, Coroneo MT. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br J Ophthalmol 1996;80:214-216.
54. Chern KG, Margolis TP, Chandler DB, Martin DF, Kuppermann BD, Wolitz RA. Glycoprotein B subtyping of cytomegalovirus strains in the vitreous of patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1998;178:1149-1153.
55. Verbraak FD, Bruinenberg M, Van den Horn GJ, et al. Cytomegalovirus (CMV) strain differences between the eye and blood in AIDS patients with CMV retinitis. AIDS 1998;12:713-718.
56. Peek R, Verbraak F, Bruinenberg M, Van den Horn G, Kijlstra A. Cytomegalovirus glycoprotein B genotyping in ocular fluids and blood of AIDS patients with cytomegalovirus retinitis. Invest Ophthalmol Vis Sci 1998;39:1183-1187.
57. Martidis A, Danis RP, Ciulla TA. Treatment of rhegmatogenous retinal detachment due to cytomegalovirus retinitis with combination pars plana vitrectomy/silicone oil and sustained-release ganciclovir implant. Invest Ophthalmol Vis Sci 1998;39:S135.
58. Buggage RR, Martin DF. Ganciclovir implants in eyes with cytomegalovirus retinal detachments repaired with silicone oil. Invest Ophthalmol Vis Sci 1998;39:S135.
59. Morley MG, Duker JS, Reichel E. Ganciclovir intraocular implant [letter; comment]. Ophthalmology 1996;103:1517.
60. Gentile RC, Lewis JM, Puklin JE. Cyclodialysis complicating intravitreal ganciclovir implantation. Arch Ophthalmol 1997;115:1204-1205.
61. Zegans ME, Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and CMV retinitis. Am J Ophthalmol 1998;125:292-300.
62. Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997;115:733-737.
63. Karavellas MP, Lowder CY, Macdonald JC, Avila CP Jr, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome. Arch Ophthalmol 1998;116:169-175.
64. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus. Am J Ophthalmol 1993;116:713-720.
65. Jabs DA, Engler C, Haller J, et al. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991;109:794-799.
66. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: The foscarnet-ganciclovir cytomegalovirus retinitis trial. Am J Ophthalmol 1997;124:61-70.
67. Krieger AE. The pars plana incision: Experimental studies, pathologic observations, and clinical experience. Trans Am Ophthalmol Soc 1991;89:549-621.
68. Martin DF, Ferris FL, Brothers RJ, et al. Retinal detachment in eyes treated with a ganciclovir implant [letter]. Arch Ophthalmol 1995;113:1355.
69. Lim JL, Wolitz RA, Dowling AH, Bloom HR, Irvine AR, Schwartz DM. Visual and anatomic outcomes associated with posterior complications following ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1999;127:288-293.
70. Meldrum ML, Aaberg TM, Patel A, Davis J. Cataract extraction after silicone oil repair of retinal detachments due to necrotizing retinitis. Arch Ophthalmol 1996;114:885-892.
71. Anand R, Font RL, Fish RH, Nightingale SD. Pathology of cytomegalovirus retinitis treated with sustained release infravitreal ganciclovir. Ophthalmology 1993;100:1032-1039.
72. Charles NC, Steiner GC. Ganciclovir intraocular implant: A clinicopathologic study. Ophthalmology 1996;103:416-421.
73. Morley MG, Duker JS, Ashton P, Robinson MR. Replacing ganciclovir implants. Ophthalmology 1995;102:388-392.
74. Krieger AE, Foos RY, Yoshizumi MO. Intravitreous granulation tissue and retinal detachment following pars plana injection for cytomegalovirus retinopathy. Graefes Arch Clin Exp Ophthalmol 1992;230:197-198.
75. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-1497.
76. Brown F, Arum I, Francis G, Patel M, Malcolm S. Ganciclovir prodrug (RS-79070): Multiple dose, dose-ranging study with effect of food. In: 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997.
77. Martin DF, Ferris FL, Parks DJ, et al. Ganciclovir implant exchange: Timing, surgical procedure, and complications. Arch Ophthalmol 1997;115:1389-1394.
78. Boyer DS, Posalski J. Potential complication associated with removal of ganciclovir implants. Am J Ophthalmol 1999;127:347-348.
79. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1997;16:15-21.